U.S. Hospitality Stock News

As major U.S. stock indexes continue to set new records, investors are navigating a landscape that seems to defy the uncertainties of a government shutdown. In such an environment, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities for those looking beyond the market giants. Despite their historically speculative reputation, these stocks can provide a blend of affordability and growth potential when backed by solid financials, making them worthy...

Viant Technology recently announced an expanded partnership with Tubi, Fox Corporation's free ad-supported streaming service, featuring a robust ID sync and deeper ad server integration, which gives advertisers improved reach and accuracy across Tubi's more than 100 million monthly active users and over 300,000 movies and TV episodes. This collaboration brings IRIS.TV's contextual and emotional data technology to Tubi's library, enabling more precise, measurable, and relevant audience...

Algoma Steel Group Inc. recently secured C$500 million in liquidity support from the Canadian and Ontario governments to address ongoing trade challenges and accelerate its business transformation, including a transition to Electric Arc Furnace steelmaking and a focus on the domestic market. This government-backed financing not only provides essential financial flexibility but also signals reinforced public support for Algoma's shift away from blast furnace operations due to U.S. tariffs,...

Murano Global Investments (MRNO) has seen its losses accelerate at a striking rate of 99.7% per year over the past five years, with its net profit margin remaining firmly in negative territory. While the stock’s Price-to-Sales Ratio of 3.3x looks cheap compared to peer group averages of 6.9x, it remains slightly above the broader US real estate industry average of 3x. Despite appearing attractively valued on this metric, persistent unprofitability and growing losses present a cautious set of...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Lionsgate Studios fair value estimate is US$5.26 Lionsgate...

If you are eyeing Vanguard Index Funds - Vanguard S&P 500 ETF and wondering whether now is the time to jump in, you are definitely not alone. The ETF has been grabbing attention as it continues a steady climb, up 1.4% in just the past week, and a robust 4.5% over the last month. Year-to-date, we have seen an impressive 14.5% gain, stacking up to a 19.4% rise over the past year. For long-term holders, it gets even better, with returns over three and five years standing at 87.3% and 109.6%,...

Global Medical REIT (GMRE) just announced a reverse stock split that will convert every five existing shares into one new share and adjust the par value of its common stock. This move is designed to streamline the share structure and is prompting fresh interest from investors curious about what it could mean for GMRE’s future trading dynamics. See our latest analysis for Global Medical REIT. After a relatively quiet year, Global Medical REIT’s reverse split has put the spotlight back on its...

JFB Construction Holdings (NasdaqCM:JFB) grabbed the spotlight after its shares jumped more than 59%, following major new infrastructure contract wins and the announcement of a fresh $43.9 million private placement last week. See our latest analysis for JFB Construction Holdings. JFB Construction’s recent 59% rally stands out against a backdrop of otherwise modest 7-day and year-to-date share price returns. Recent contract wins and a leadership hire have sparked fresh investor optimism. While...

89bio (ETNB) shares have been on the move lately, with investors eyeing recent performance trends and weighing potential growth. The stock posted a 62% gain over the past month, which has turned heads in the biotech sector. See our latest analysis for 89bio. Momentum is definitely building for 89bio, with a strong 1-month share price return of 61.5% and noticeable buzz stemming from recent sector activity. That kind of move stands out even more when you consider the company’s 1-year total...

NeoVolta has been making headlines with its recently reported jump in sales, the release of new commercial and industrial energy storage solutions, and an announcement of plans to acquire key assets from Neubau Energy. These moves came after news of the company’s addition to the S&P Global BMI Index, catching the attention of investors looking for growth stories in energy storage. See our latest analysis for NeoVolta. On the heels of its index addition and those recent new product launches,...

BlackRock’s iShares Bitcoin Trust ETF has recently overtaken Deribit as the world’s largest venue for Bitcoin options trading, marking a major shift toward regulated, U.S.-based digital asset markets. This transition reflects a meaningful increase in institutional demand and signals Wall Street’s expanding influence over both spot and derivatives crypto markets. We’ll explore how IBIT’s rapid leadership in the Bitcoin options market cements its evolving role in institutional digital asset...

VisionSys AI (VSA) continues to operate at a loss, but over the past five years, the company has managed to cut its losses by an average of 30.3% per year. While its Price-to-Sales Ratio stands at 1.6x, matching the US Consumer Services industry average and notably lower than the peer group’s 5.8x, there is still no clear sign of profit growth momentum or improvement in net profit margins. Investors are left weighing a steadily improving loss profile and apparently attractive valuation...

As U.S. markets continue to rise, with major indices setting fresh records despite concerns over a government shutdown, investors are exploring opportunities beyond the traditional blue-chip stocks. Penny stocks, often seen as relics of past speculative trading days, still hold potential when backed by strong financials and solid business models. These smaller or newer companies can offer unique growth prospects and hidden value for those willing to explore beyond the well-trodden paths of...

Ellomay Capital (NYSEAM:ELLO) remains unprofitable, with no evidence of a positive net profit margin or high-quality past earnings, but has managed to reduce its losses by an average of 4.7% per year over the past five years. While investors may note the company's progress on trimming losses, ongoing concerns around financial stability and a premium valuation compared to the industry average may weigh on sentiment. See our full analysis for Ellomay Capital. Next, we will see how the latest...

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...

Despite an already strong run, Harrow, Inc. ( NASDAQ:HROW ) shares have been powering on, with a gain of 27% in the...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by buying...

Ternium S.A.'s ( NYSE:TX ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy right now...

To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

With the business potentially at an important milestone, we thought we'd take a closer look at XOMA Royalty...

In late September 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b trial of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults, observing faster symptom resolution and a lower hospitalization rate despite not meeting the trial's primary endpoint. This proof-of-concept success provides the company with clear support to advance zelicapavir into Phase 3 development, potentially addressing significant unmet needs in the RSV market for...

Soft earnings didn't appear to concern H.B. Fuller Company's ( NYSE:FUL ) shareholders over the last week. Our analysis...